vested
Sino Biopharmaceutical (1177 HK)
Completed Acquisition On F-star; Expecting Double-digit Growth For 2023
Sino Biopharm has obtained CFIUS approval and completed the acquisition of F-star.
It strengthened its R&D pipeline by adding three clinical-stage bsAbs.
Despite the impact from the COVID-19 outbreak in 4Q22 and 1Q23, we believe the company
may see strong business recovery from Feb 23.
We expect its revenue to grow by 10.2% yoy and 15.2% yoy in 2022 and 2023.
Its abundant cash may also provide huge M&A and BD opportunities.
Maintain HOLD and target price of HK$4.80.
Source: UOBKH
https://research.uobkayhian.com/content ... b0b3dde376
|
|
Sino Biopharm 1177
Re: Sino Biopharm 1177
by winston » Fri Mar 10, 2023 10:28 am
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Fri Mar 31, 2023 6:37 pm
vested
SINO BIOPHARM (01177.HK) 2022 NP Craters 82.6% to RMB2.544B; Final DPS HK6 Cents
SINO BIOPHARM (01177.HK) announced the financial results for the year ended 31 December 2022.
The revenue of the period amounted to RMB28.78 billion, up 7.1% YoY.
The net profit cratered 82.6% YoY to RMB2.544 billion.
EPS was RMB13.66 fen.
Dividend History
Announce Date Event Particular
2022/08/23 Interim D:HKD 0.0600
2022/03/31 Final D:HKD 0.0400
2021/08/31 Interim D:HKD 0.0200
2021/05/24 Quarter 1 D:HKD 0.0200
A final dividend of HK6 cents per share was declared against a dividend of HK4 cents per share in the corresponding period of the previous year.
Together with the interim dividend of HK6 cents, the full-year DPS amounted to HK12 cents.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... t-news/HK6
SINO BIOPHARM (01177.HK) 2022 NP Craters 82.6% to RMB2.544B; Final DPS HK6 Cents
SINO BIOPHARM (01177.HK) announced the financial results for the year ended 31 December 2022.
The revenue of the period amounted to RMB28.78 billion, up 7.1% YoY.
The net profit cratered 82.6% YoY to RMB2.544 billion.
EPS was RMB13.66 fen.
Dividend History
Announce Date Event Particular
2022/08/23 Interim D:HKD 0.0600
2022/03/31 Final D:HKD 0.0400
2021/08/31 Interim D:HKD 0.0200
2021/05/24 Quarter 1 D:HKD 0.0200
A final dividend of HK6 cents per share was declared against a dividend of HK4 cents per share in the corresponding period of the previous year.
Together with the interim dividend of HK6 cents, the full-year DPS amounted to HK12 cents.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... t-news/HK6
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Wed Apr 26, 2023 12:34 pm
vested
HSBC Global Research Drops SINO BIOPHARM (01177.HK) TP to $6.3, Rates Buy
HSBC Global Research has decreased the target price of SINO BIOPHARM (01177.HK) from $6.5 to $6.3 and kept its Buy rating in a recent report.
HSBC noted that the revenue of SINO BIOPHARM has increased by 7.1% last year, which was lower than expected, mainly due to the impact of the pandemic, resulting in lower revenue in the fourth quarter.
The broker lowered its revenue forecast for this year and next by 5% and 8% respectively, while remaining optimistic about the company's innovative pharmaceutical R&D transformation process.
The broker expected its revenue to grow at a CAGR of 11% from 2022 to 2025.
On the cost side, HSBC stated that the company's cost of sales rate improved last year, mainly due to cost optimization, so it lowered its cost of sales forecast by 12% and 14% for this year and next respectively, and expected the company's EBIT to grow at a CAGR of 9% in 2022-25.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... -news/AAFN
HSBC Global Research Drops SINO BIOPHARM (01177.HK) TP to $6.3, Rates Buy
HSBC Global Research has decreased the target price of SINO BIOPHARM (01177.HK) from $6.5 to $6.3 and kept its Buy rating in a recent report.
HSBC noted that the revenue of SINO BIOPHARM has increased by 7.1% last year, which was lower than expected, mainly due to the impact of the pandemic, resulting in lower revenue in the fourth quarter.
The broker lowered its revenue forecast for this year and next by 5% and 8% respectively, while remaining optimistic about the company's innovative pharmaceutical R&D transformation process.
The broker expected its revenue to grow at a CAGR of 11% from 2022 to 2025.
On the cost side, HSBC stated that the company's cost of sales rate improved last year, mainly due to cost optimization, so it lowered its cost of sales forecast by 12% and 14% for this year and next respectively, and expected the company's EBIT to grow at a CAGR of 9% in 2022-25.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... -news/AAFN
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Tue Jul 25, 2023 11:15 am
vested
Sino Biopharmaceutical (1177 HK)
Expects 1H23 Revenue To Be Flat From 1H22; Lowers 2023 Revenue Growth
Guidance To Single Digits
Sino Biopharm expects 1H23 revenue to be flat yoy.
The sluggish revenue growth was mainly due to:
a) the COVID-19 outbreak significantly impacted the company’s 1Q23 sales performance, and
b) oncology products failed to maintain their sales momentum in 2Q23.
The company has also lowered its yoy revenue growth guidance from double digits to single digits for 2023.
Maintain HOLD and target price of HK$3.70, based on SOTP valuation, comprising:
a) HK$1.72/share at 9x 2023F PE for existing drugs, and
b) NAV-derived pipeline value of HK$1.98/share (10.1% WACC, 3.5% perpetual growth rate).
Source: UOBKH
https://research.uobkayhian.com/content ... 3fb41b8146
Sino Biopharmaceutical (1177 HK)
Expects 1H23 Revenue To Be Flat From 1H22; Lowers 2023 Revenue Growth
Guidance To Single Digits
Sino Biopharm expects 1H23 revenue to be flat yoy.
The sluggish revenue growth was mainly due to:
a) the COVID-19 outbreak significantly impacted the company’s 1Q23 sales performance, and
b) oncology products failed to maintain their sales momentum in 2Q23.
The company has also lowered its yoy revenue growth guidance from double digits to single digits for 2023.
Maintain HOLD and target price of HK$3.70, based on SOTP valuation, comprising:
a) HK$1.72/share at 9x 2023F PE for existing drugs, and
b) NAV-derived pipeline value of HK$1.98/share (10.1% WACC, 3.5% perpetual growth rate).
Source: UOBKH
https://research.uobkayhian.com/content ... 3fb41b8146
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Sun Aug 27, 2023 10:50 am
vested
SINO BIOPHARM (01177.HK) Interim Net Profit RMB1.259B, Down 34.5%; Div $2 Cents
SINO BIOPHARM (01177.HK) announced its interim results for the six months ended June this year, with revenue of RMB15.277 billion, up 0.5% YoY.
Net profit of RMB1.259 billion, down 34.5% YoY, giving an EPS of RMB6.78 cents.
An interim dividend of HK$2 cents was declared, compared to HK$6 cents in the same period last year.
Dividend History
Announce Date Event Particular
2023/03/31 Final D:HKD 0.0600
2022/08/23 Interim D:HKD 0.0600
2022/03/31 Final D:HKD 0.0400
2021/08/31 Interim D:HKD 0.0200
At the end of the reporting period, the group had 127 products under development, including 60 oncology products, 10 liver disease products, 21 respiratory system products, 17 surgery/analgesia products, and 19 products in other categories, 69 of which were Category I innovative products.
Sinovac Life Sciences, a company that is mainly engaged in the R&D, production and sales of human vaccines and in which the group holds 15.03% equity interests, was the developer of Covid-19 vaccine CoronaVac, with a global supply of more than 2.9 billion doses.
However, as the market environment continues to change, the sales volume of CoronaVac decreased and the financial performance of Sinovac Life Sciences was lowered YoY.
The group noted that in the next three years, close to 10 innovative drugs developed by it will be launched to market, and more than 40 innovative drugs under research and development have the potential to be launched by 2030.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... -news/AAFN
SINO BIOPHARM (01177.HK) Interim Net Profit RMB1.259B, Down 34.5%; Div $2 Cents
SINO BIOPHARM (01177.HK) announced its interim results for the six months ended June this year, with revenue of RMB15.277 billion, up 0.5% YoY.
Net profit of RMB1.259 billion, down 34.5% YoY, giving an EPS of RMB6.78 cents.
An interim dividend of HK$2 cents was declared, compared to HK$6 cents in the same period last year.
Dividend History
Announce Date Event Particular
2023/03/31 Final D:HKD 0.0600
2022/08/23 Interim D:HKD 0.0600
2022/03/31 Final D:HKD 0.0400
2021/08/31 Interim D:HKD 0.0200
At the end of the reporting period, the group had 127 products under development, including 60 oncology products, 10 liver disease products, 21 respiratory system products, 17 surgery/analgesia products, and 19 products in other categories, 69 of which were Category I innovative products.
Sinovac Life Sciences, a company that is mainly engaged in the R&D, production and sales of human vaccines and in which the group holds 15.03% equity interests, was the developer of Covid-19 vaccine CoronaVac, with a global supply of more than 2.9 billion doses.
However, as the market environment continues to change, the sales volume of CoronaVac decreased and the financial performance of Sinovac Life Sciences was lowered YoY.
The group noted that in the next three years, close to 10 innovative drugs developed by it will be launched to market, and more than 40 innovative drugs under research and development have the potential to be launched by 2030.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... -news/AAFN
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Mon Aug 28, 2023 8:57 am
vested
Sino Biopharmaceutical (1177 HK)
1H23: Revenue And Adjusted Earnings Flat; Maintain Positive Revenue Growth
Guidance For 2023
Sino Biopharm posted slow 1H23 revenue growth of 0.5% yoy, and adjusted net earnings rose by 1.2% yoy, due to the significant impact from the unprecedented COVID-19 outbreak in 1Q23.
Management maintains its guidance of positive revenue growth for 2023.
The challenging business environment may cloud the revenue growth outlook of the company in the short term.
Maintain HOLD with a lower target price of HK$3.00.
Maintain HOLD with a lower target price of HK$3.00, based on SOTP valuation,
comprising:
a) HK$1.10/share at 6x 2024F PE for existing drugs, and
b) NAV-derived
pipeline value of HK$1.90/share (11.1% WACC, 3.5% perpetual growth rate).
Source: UOBKH
https://research.uobkayhian.com/content ... c5c6def97d
Sino Biopharmaceutical (1177 HK)
1H23: Revenue And Adjusted Earnings Flat; Maintain Positive Revenue Growth
Guidance For 2023
Sino Biopharm posted slow 1H23 revenue growth of 0.5% yoy, and adjusted net earnings rose by 1.2% yoy, due to the significant impact from the unprecedented COVID-19 outbreak in 1Q23.
Management maintains its guidance of positive revenue growth for 2023.
The challenging business environment may cloud the revenue growth outlook of the company in the short term.
Maintain HOLD with a lower target price of HK$3.00.
Maintain HOLD with a lower target price of HK$3.00, based on SOTP valuation,
comprising:
a) HK$1.10/share at 6x 2024F PE for existing drugs, and
b) NAV-derived
pipeline value of HK$1.90/share (11.1% WACC, 3.5% perpetual growth rate).
Source: UOBKH
https://research.uobkayhian.com/content ... c5c6def97d
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Wed Oct 04, 2023 9:21 am
vested
SINO BIOPHARM Intends to Buy Back Max. $1B of Shrs in Coming Yr
SINO BIOPHARM (01177.HK) announced that it resolved to approve a share purchase plan on 3 October.
The Company will, subject to market conditions, buy back ordinary shares of the Company from the open market, and under the restricted share award scheme adopted by the Company on 5 January 2018, instruct the trustee responsible for administering the share award scheme to purchase shares from the open market, for not exceeding $1 billion over the next 12 months.
The Board will review from time to time, and determine at its sole discretion how the share purchase amount will be allocated between the buyback of shares and the purchase of award shares.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... -news/AAFN
SINO BIOPHARM Intends to Buy Back Max. $1B of Shrs in Coming Yr
SINO BIOPHARM (01177.HK) announced that it resolved to approve a share purchase plan on 3 October.
The Company will, subject to market conditions, buy back ordinary shares of the Company from the open market, and under the restricted share award scheme adopted by the Company on 5 January 2018, instruct the trustee responsible for administering the share award scheme to purchase shares from the open market, for not exceeding $1 billion over the next 12 months.
The Board will review from time to time, and determine at its sole discretion how the share purchase amount will be allocated between the buyback of shares and the purchase of award shares.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... -news/AAFN
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Fri Oct 27, 2023 1:35 pm
vested
Oct 18, 2023
BofAS Axes SINO BIOPHARM (01177.HK) TP to $4, Keeps Rating at Buy
BofA Securities issued a research report saying that it lowered its revenue forecast for SINO BIOPHARM (01177.HK) based on the Company's sales figures for 8M23 and the anti-corruption campaign in Mainland China, resulting in a 2% decrease in the total revenue forecasts for 2023 to 2025, respectively.
In addition, BofA Securities updated its beta assumption on SINO BIOPHARM to 1.05 from 0.92 to reflect stock volatility, thereby adjusting the weighted average cost of capital (WACC) to 10.3% from the previous 9.5%.
BofA Securities axed its target price to $4 from $4.7 and reiterated rating at Buy, reflecting the Company's strong research and development capability and progress in product pipeline.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/analy ... stock-news
Oct 18, 2023
BofAS Axes SINO BIOPHARM (01177.HK) TP to $4, Keeps Rating at Buy
BofA Securities issued a research report saying that it lowered its revenue forecast for SINO BIOPHARM (01177.HK) based on the Company's sales figures for 8M23 and the anti-corruption campaign in Mainland China, resulting in a 2% decrease in the total revenue forecasts for 2023 to 2025, respectively.
In addition, BofA Securities updated its beta assumption on SINO BIOPHARM to 1.05 from 0.92 to reflect stock volatility, thereby adjusting the weighted average cost of capital (WACC) to 10.3% from the previous 9.5%.
BofA Securities axed its target price to $4 from $4.7 and reiterated rating at Buy, reflecting the Company's strong research and development capability and progress in product pipeline.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/analy ... stock-news
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Tue Apr 02, 2024 3:32 pm
vested
Sino Biopharmaceutical (1177 HK)
2023: Results In Line; Expects Revenue Growth To Accelerate In 2024
Sino Biopharm posted flat 2023 revenue growth of 0.7% yoy and a 1.5% yoy rise in adjusted net earnings, in line with our estimates.
We expect its newly-launched biosimilar products to support a stronger revenue growth of about 9.7% in 2024.
It also targets to launch four new innovative products this year, which will brighten the growth outlook for 2024-26.
Upgrade to BUY with a higher target price of HK$3.80, based on SOTP valuation comprising:
a) HK$1.34/share at 8x 2024F PE for existing drugs, and
b) NAV-derived pipeline value of HK$2.46/share (11.0% WACC, 3.5% perpetual growth rate).
Source: UOBKH
https://research.uobkayhian.com/content ... 72d94575de
Sino Biopharmaceutical (1177 HK)
2023: Results In Line; Expects Revenue Growth To Accelerate In 2024
Sino Biopharm posted flat 2023 revenue growth of 0.7% yoy and a 1.5% yoy rise in adjusted net earnings, in line with our estimates.
We expect its newly-launched biosimilar products to support a stronger revenue growth of about 9.7% in 2024.
It also targets to launch four new innovative products this year, which will brighten the growth outlook for 2024-26.
Upgrade to BUY with a higher target price of HK$3.80, based on SOTP valuation comprising:
a) HK$1.34/share at 8x 2024F PE for existing drugs, and
b) NAV-derived pipeline value of HK$2.46/share (11.0% WACC, 3.5% perpetual growth rate).
Source: UOBKH
https://research.uobkayhian.com/content ... 72d94575de
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Re: Sino Biopharm 1177
by winston » Fri Apr 05, 2024 6:13 pm
vested
<Research>G Sachs Lowers TP of SINO BIOPHARM (01177.HK) to $4.02; 2H23 Weak as Expected
Goldman Sachs released a research report on SINO BIOPHARM (01177.HK).
The pharma's sales of major product categories in 2H23 were weak amid the unfavourable policy environment of the industry.
Gross profit margin also fell, mainly due to changes in the company's revenue structure.
The decline in operating income was offset by a reduction in selling expenses, which was mainly due to the company's proactive cost-control measures, as well as the disruption in sales and marketing activities in 3Q23, bringing mixed results for the company.
The broker attributed the decline in SINO BIOPHARM's profitability to the loss-making situation of its associates.
Company management reiterated its guidance for double-digit sales growth this year as the impact of anti-corruption and Covid diminishes, with earnings dependent on overseas R&D expenditures.
In addition, Goldman reduced its 2024 and 2025 profit forecasts on SINO BIOPHARM by 22.4% and 22.8% respectively, reflecting the company's performance in 2H23 and divestitures.
The broker also expected the pharma's profit growth to become stronger in the next two years, with more business development (BD) deals likely to come.
Goldman lowered its target price on SINO BIOPHARM from $4.3 to $4.02 and rated the company Buy.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... -news/AAFN
<Research>G Sachs Lowers TP of SINO BIOPHARM (01177.HK) to $4.02; 2H23 Weak as Expected
Goldman Sachs released a research report on SINO BIOPHARM (01177.HK).
The pharma's sales of major product categories in 2H23 were weak amid the unfavourable policy environment of the industry.
Gross profit margin also fell, mainly due to changes in the company's revenue structure.
The decline in operating income was offset by a reduction in selling expenses, which was mainly due to the company's proactive cost-control measures, as well as the disruption in sales and marketing activities in 3Q23, bringing mixed results for the company.
The broker attributed the decline in SINO BIOPHARM's profitability to the loss-making situation of its associates.
Company management reiterated its guidance for double-digit sales growth this year as the impact of anti-corruption and Covid diminishes, with earnings dependent on overseas R&D expenditures.
In addition, Goldman reduced its 2024 and 2025 profit forecasts on SINO BIOPHARM by 22.4% and 22.8% respectively, reflecting the company's performance in 2H23 and divestitures.
The broker also expected the pharma's profit growth to become stronger in the next two years, with more business development (BD) deals likely to come.
Goldman lowered its target price on SINO BIOPHARM from $4.3 to $4.02 and rated the company Buy.
Source: AAStocks Financial News
http://www.aastocks.com/en/stocks/news/ ... -news/AAFN
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118906
- Joined: Wed May 07, 2008 9:28 am
Who is online
Users browsing this forum: No registered users and 10 guests